Please Enable Cookies

www.laserfocusworld.com is using a security service for protection against online attacks. This process is automatic. You will be redirected once the validation process is complete.

Recent Quotes
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Barinthus Biotherapeutics plc - American Depositary Shares (NQ: BRNS )

1.280 UNCHANGED
Streaming Delayed Price Updated: 3:56 PM EDT, Aug 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 1.280
Bid (Size) 1.220 (2)
Ask (Size) 2.060 (2)
Prev. Close 1.280
Today's Range 1.280 - 1.280
52wk Range 1.180 - 5.000
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BRNS Stock Earnings: Barinthus Biotherapeutics Misses EPS for Q2 2024
BRNS stock results show that Barinthus Biotherapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results
From Barinthus Biotherapeutics
Via GlobeNewswire

Performance

YTD
-65.41%
-65.41%
1 Month
-14.67%
-14.67%
3 Month
-36.00%
-36.00%
6 Month
-54.77%
-54.77%
1 Year
-68.78%
-68.78%

More News

Read More
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
From Sagimet Biosciences Inc.
Via GlobeNewswire
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Barinthus Biotherapeutics: Q4 Earnings Insights
Via Benzinga
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
From Barinthus Biotherapeutics
Via GlobeNewswire
Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
From Barinthus Biotherapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Barinthus Bio to Present VTP-300 Clinical Data Updates at EASL Congress 2024
From Barinthus Biotherapeutics
Via GlobeNewswire
BRNS Stock Earnings: Barinthus Biotherapeutics Beats EPS for Q1 2024
Via InvestorPlace
Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments
From Barinthus Biotherapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer
From Barinthus Biotherapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Infection-Focused Barinthus Bio's VTP-200 Data Underwhelming: Analyst Weighs On Mixed Perspectives
Via Benzinga
Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections
From Barinthus Biotherapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
BRNS Stock Earnings: Barinthus Biotherapeutics Beats EPS for Q4 2023
Via InvestorPlace
Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments
From Barinthus Biotherapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones
From Barinthus Biotherapeutics
Via GlobeNewswire
New partnership aims to advance vaccine against MERS coronavirus
From Barinthus Biotherapeutics
Via GlobeNewswire
Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD
From Barinthus Biotherapeutics
Via GlobeNewswire
Barinthus Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Developments
From Barinthus Biotherapeutics
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.